Hyperpolarized 13C-pyruvate: Hyperpolarized 13C-pyruvate is injected intravenously at a dose of 0.43 mL/kg body weight, and at a rate of 5 mL/second followed by a 20 mL saline flush at 5 mL/second when the patient is already in the MRI scanner
Study summary
Positron emission tomography with 18F fluorodeoxyglucose (FDG) is the conventional imaging technique to provide information regarding tissue glucose uptake and has been highly clinically successful. However, it cannot assess downstream metabolism, which may be useful in the diagnosis and assessment of treatment response in a variety of diseases. Patients will also be exposed to ionizing radiation, the amount of exposure can vary depending on the dose of tracer administered, frequency of scans and duration of each scan. Carbon-13 (13C) magnetic resonance imaging (MRI) is particularly attractive for metabolic imaging because carbon serves as the backbone of nearly all organic molecules in the body. With this technique, the polarization increases to approximately 30%-40%, an increase of over 10,000 to 100,000-fold, thereby dramatically increasing the MRI signal . Whilst the role of 13C imaging has been demonstrated in many sites around the world, we aim to demonstrate the feasibility and application of 13C hyperpolarized imaging in healthy Singapore residents and patients with cardiovascular and/or cardiometabolic diseases.
Eligibility
Sex
ALL
Min age
21 Years
Max age
99 Years
Healthy volunteers
Accepted
Inclusion Criteria:
Healthy Volunteers:
1. Age 21 years and above
2. No significant medical co-morbidities (such as chronic kidney disease, diabetes mellitus, heart failure, ischemic heart disease, previous strokes)
3. No history of cancer
4. Able and willing to comply with study procedures and provide signed informed consent
Patients with cardiovascular/cardiometabolic diseases:
1. Age 21 years and above
2. Physician diagnosed cardiovascular conditions: ischemic heart disease, inherited cardiomyopathies (hypertrophic, dilated or infiltrative cardiomyopathies) and stable heart failure; and/or
3. Cardiometabolic conditions (such as diabetes on medications, hypertension, central obesity, fatty liver disease)
4. Able and willing to comply with study procedures and provide signed informed consent
Exclusion Criteria:
1. Standard contraindications for magnetic resonance procedures (such as implantable medical devices, suspected presence of surgical apparatus or shrapnel, severe claustrophobia)
2. Unstable medical conditions (such as symptomatic heart failure, unstable hypertension/glucose levels as determined by investigators, symptomatic arrhythmias, angina)
3. Pregnant or nursing women
4. Known allergies to pyruvate or any of its components
Primary outcome measure(s)
Feasibility and reproducibility of Imaging Technique — 30 - 45 minutes post dose Feasibility and reproducibility of the imaging technique in healthy volunteers and patients with cardiovascular and/or cardiometabolic diseases
Trial sites (1)
Facility
City
Region
Status
National Heart Centre Singapore
Singapore
Singapore
Recruiting
More National Heart Centre Singapore trials in Singapore
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.